Lung Cancer News

Data from a phase 3 trial designed to compare pralsetinib with standard therapy for certain patients with advanced lung cancer revealed a risk for severe — and potentially fatal — infections with the drug, according to its manufacturer.

Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced diabetes, according to results of a cohort study.

People with cancer had more than double the risk for COVID-19 mortality than the general population, according to study results.

Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.

The use of chatbot tools may be a valuable part of health management strategies to improve access to cancer genetic services, according to study results.

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.

Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.

The FDA approved tumor treating fields for use as part of combination treatment for certain patients with metastatic non-small cell lung cancer.

The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer.

Although progress has been made, lack of diversity continues to be problematic in trials of immune checkpoint inhibitors, according to study results.